Trial Profile
A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 3a Formulation of Liraglutide (Formulation 4) and the Planned Phase 3b Formulation (Final Formulation 4)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 31 Jan 2012 New trial record